Gefitinib in the adjuvant setting: Safety results from a phase III study in patients with completely resected non-small cell lung cancer

Anti-Cancer Drugs

Volumn 16, Issue 10, 2005, Pages 1123-1128

  Tsuboi, Masahiro ^a   Kato, Harubumi ^a   Nagai, Kanji ^b   Tsuchiya, Ryosuke ^c   Wada, Hiromi ^d   Tada, Hirohito ^e   Ichinose, Yukito ^f   Fukuoka, Masahiro ^g   Jiang, Haiyi ^h  

^a TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d KYOTO UNIVERSITY FACULTY OF MEDICINE   (Japan)

^e OSAKA CITY GENERAL HOSPITAL   (Japan)

^f NATIONAL KYUSHU CANCER CENTER   (Japan)

^g KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h ASTRAZENECA   (United Kingdom)

Author keywords

Gefitinib; Non small cell lung cancer; Phase III; Safety

Indexed keywords

GEFITINIB; PLACEBO;

ACNE; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG SAFETY; DRY SKIN; DYSPNEA; ECZEMA; FATIGUE; FEMALE; FOLLOW UP; GASTRITIS; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; IMPETIGO; INTERSTITIAL LUNG DISEASE; JAPAN; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PARONYCHIA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; QUINAZOLINES;

EID: 27644484102     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200511000-00012     Document Type: Article

References (18)

1. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. SEER cancer statistics review; 2004. http://seer.cancer.gov/csr/1975_2001/.
2. Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995; 109:120-129.
3. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350:1713-1721.
4. Wada H, Hitomi S, Teramatsu T. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol 1996; 14:1048-1054.
5. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311:899-909.
6. Tanaka F, Miyahara R, Ohtake Y, Yanagihara K, Fukuse T, Hitomi S, et al. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg 1998; 14:256-262.
7. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351-360.
8. Endo C, Saito Y, Iwanami H, Tsushima T, Imai T, Kawamura M, et al. A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery. Lung Cancer 2003; 40:181-186.
9. Wada H, Miyahara R, Tanaka F, Hitomi S. Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegafur) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG). Eur J Cardiothorac Surg 1999; 15:438-443.
10. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J-Y, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2237-2246.
11. Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. J Am Med Ass 2003; 290:2149-2158.
12. Ochs J, Grous JJ, Warner KL. Final survival and safety results for 21,064 non-small-cell lung cancer (NSCLC) patients who received compassionate use gefitinib in a U.S. expanded access program (EAP). Proc Am Soc Clin Oncol 2004; 23:628.
13. Onn A, Tsuboi M, Thatcher N. Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib. Br J Cancer 2004; 91(Suppl 2):S11-S17.
14. World Medical Association. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. J Am Med Ass 1997; 277:925-926.
15. Sato A, Toyoshima M, Kondo A, Ohta K, Sato H, Ohsumi A. Pneumonitis induced by the herbal medicine Sho-saiko-to in Japan. Nihon Kyobu Shikkan Gakkai Zasshi 1997; 35:391-395.
16. Tohyama M, Tamaki Y, Toyama M, Ishimine T, Miyazato A, Nakamoto A, et al. A case of loxoprofen-induced pneumonitis pathologically resembling hypersensitivity pneumonitis. Nihon Kokyuki Gakkai Zasshi 2002; 40:123-128.
17. Miyazaki E, Ando M, Ih K, Matsumoto T, Kaneda K, Tsuda T. [Pulmonary edema associated with the Chinese medicine shosaikoto]. Nihon Kokyuki Gakkai Zasshi 1998; 36:776-780.
18. Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (IRESSA™) monotherapy. Clinical experience in non-small-cell lung cancer. Drug Safety 2004; 27:1081-1092.